1140509

氯草酸钾

United States Pharmacopeia (USP) Reference Standard

• 别名: 氯拉卓酸 二钾盐, 7-氯-2,3-二氢-2,2-二羟基-5-苯基-1H-1,4-苯二氮卓-3-羧酸
• 线性分子式: C₁₆H₁₁ClN₂O₄K₂
• CAS号: 57109-90-7
• 分子量: 408.92
• 分類程式碼代碼: 41116107
• NACRES: NA.24

属性

• 等級: pharmaceutical primary standard
• API 家族: clorazepate
• 製造商／商標名: USP
• 藥物控制: USDEA Schedule IV; regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)
• 應用: pharmaceutical (small molecule)
• 格式: neat
• SMILES 字串: ClC1=CC=C2C(C(C3=CC=CC=C3)=NC(C(O[K])=O)C(N2)=O)=C1.[K]O
• InChI: 1S/C16H11ClN2O3.2K.H2O/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12;;;/h1-8,14H,(H,18,20)(H,21,22);;;1H2/q;2*+1;/p-2
• InChI 密鑰: QCHSEDTUUKDTIG-UHFFFAOYSA-L
• 基因資訊: human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879)

说明

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Clorazepate dipotassium USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Clorazepate Dipotassium Tablets

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

安全信息

• 象形圖: GHS08,GHS07
• 訊號詞: Warning
• 危險聲明: H302,H361
• 防範說明: P280 - P301 + P312 + P330
• 危險分類: Acute Tox. 4 Oral - Repr. 2
• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable